These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38535994)

  • 61. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
    Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
    [TBL] [Abstract][Full Text] [Related]  

  • 62. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
    Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies.
    Kita Y; Hamada A; Saito R; Teramoto Y; Tanaka R; Takano K; Nakayama K; Murakami K; Matsumoto K; Akamatsu S; Yamasaki T; Inoue T; Tabata Y; Okuno Y; Ogawa O; Kobayashi T
    Br J Cancer; 2019 Dec; 121(12):1027-1038. PubMed ID: 31673101
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular mechanisms of cisplatin resistance in bladder cancer.
    Drayton RM; Catto JW
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):271-81. PubMed ID: 22316374
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer.
    Li F; Zhang H; Huang Y; Li D; Zheng Z; Xie K; Cao C; Wang Q; Zhao X; Huang Z; Chen S; Chen H; Fan Q; Deng F; Hou L; Deng X; Tan W
    Drug Resist Updat; 2024 Mar; 73():101059. PubMed ID: 38295753
    [TBL] [Abstract][Full Text] [Related]  

  • 66. β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas.
    Li QQ; Wang G; Liang H; Li JM; Huang F; Agarwal PK; Zhong Y; Reed E
    Anticancer Res; 2013 Apr; 33(4):1421-8. PubMed ID: 23564782
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma.
    Hastings JF; Gonzalez Rajal A; Latham SL; Han JZ; McCloy RA; O'Donnell YE; Phimmachanh M; Murphy AD; Nagrial A; Daneshvar D; Chin V; Watkins DN; Burgess A; Croucher DR
    Elife; 2020 Jun; 9():. PubMed ID: 32513387
    [TBL] [Abstract][Full Text] [Related]  

  • 68. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.
    Moon du G; Lee SE; Oh MM; Lee SC; Jeong SJ; Hong SK; Yoon CY; Byun SS; Park HS; Cheon J
    Int J Oncol; 2014 Sep; 45(3):1027-35. PubMed ID: 24969552
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1.
    Cheng R; Lu C; Zhang G; Zhang G; Zhao G
    Oncol Rep; 2017 Apr; 37(4):2129-2136. PubMed ID: 28350100
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cuprous oxide nanoparticles trigger reactive oxygen species-induced apoptosis through activation of erk-dependent autophagy in bladder cancer.
    Xiong Q; Liu A; Ren Q; Xue Y; Yu X; Ying Y; Gao H; Tan H; Zhang Z; Li W; Zeng S; Xu C
    Cell Death Dis; 2020 May; 11(5):366. PubMed ID: 32409654
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells.
    Okubo K; Isono M; Asano T; REßING N; Schulz WA; Hansen FK; Sato A
    Anticancer Res; 2021 Jun; 41(6):2901-2912. PubMed ID: 34083281
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PRDX2 regulates stemness contributing to cisplatin resistance and metastasis in bladder cancer.
    Li P; Wang W; Zhu B; Wang Y; Li J; Wang C; Wang C; Li Q
    Environ Toxicol; 2024 May; 39(5):2869-2880. PubMed ID: 38294069
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
    Zhou Q; Wu H; Miao F; Cao Y; Liang L; Huang J; Qian Z
    Anticancer Drugs; 2023 Oct; 34(9):1046-1057. PubMed ID: 37578814
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vitamin D3 sensitizes resistant human bladder cancer cells to cisplatin by regulating Sirtuin 1 gene expression.
    Di YC; Zhang ZH; Sun YP; Song J
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(20):7656-7666. PubMed ID: 36314337
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
    Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
    Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo Study.
    Hsu FS; Lin WC; Kuo KL; Chiu YL; Hsu CH; Liao SM; Dong JR; Liu SH; Chang SC; Yang SP; Chen YT; Chang RJ; Huang KH
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769137
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.
    Kashiwagi E; Ide H; Inoue S; Kawahara T; Zheng Y; Reis LO; Baras AS; Miyamoto H
    Oncotarget; 2016 Aug; 7(31):49169-49179. PubMed ID: 27322140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.